Mark Jeffrey DeLong net worth and biography

Mark DeLong Biography and Net Worth

Mr. Mark DeLong is the SVP of Apellis Pharmaceuticals.

What is Mark Jeffrey DeLong's net worth?: The estimated net worth of Mark Jeffrey DeLong is at least $1.93 million as of February 11th, 2025. Mr. DeLong owns 83,945 shares of Apellis Pharmaceuticals stock worth more than $1,930,735 as of March 31st. This net worth estimate does not reflect any other assets that Mr. DeLong may own. Learn More about Mark Jeffrey DeLong's net worth.
How do I contact Mark Jeffrey DeLong?: The corporate mailing address for Mr. DeLong and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at investors@apellis.com. Learn More on Mark Jeffrey DeLong's contact information.
Has Mark Jeffrey DeLong been buying or selling shares of Apellis Pharmaceuticals?: Over the course of the past ninety days, Mark Jeffrey DeLong has sold $10,360.02 in Apellis Pharmaceuticals stock. Most recently, Mark Jeffrey Delong sold 363 shares of the business's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $28.54, for a transaction totalling $10,360.02. Following the completion of the sale, the insider now directly owns 83,945 shares of the company's stock, valued at $2,395,790.30. Learn More on Mark Jeffrey DeLong's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 29 times. They sold a total of 292,131 shares worth more than $12,067,071.01. The most recent insider tranaction occured on March, 17th when CAO James George Chopas sold 183 shares worth more than $4,542.06. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 3/17/2025.

Mark Jeffrey DeLong Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/11/2025	Sell	363	$28.54	$10,360.02	83,945
3/18/2024	Sell	9,913	$56.90	$564,049.70	54,693
10/23/2023	Sell	131	$46.04	$6,031.24	51,622
8/17/2022	Sell	5,000	$69.50	$347,500.00	29,250
8/11/2022	Sell	5,000	$67.00	$335,000.00	29,250
7/27/2022	Sell	5,000	$57.00	$285,000.00	29,250
7/19/2022	Sell	5,000	$56.42	$282,100.00	29,250
6/16/2022	Sell	10,000	$41.78	$417,800.00	29,250
4/20/2022	Sell	7,000	$52.53	$367,710.00	28,481
7/21/2021	Sell	1,000	$65.00	$65,000.00	10,490
7/15/2021	Sell	1,000	$62.30	$62,300.00	10,490
6/15/2021	Sell	4,000	$64.96	$259,840.00	13,490
5/18/2021	Sell	2,000	$55.00	$110,000.00

Mark Jeffrey DeLong Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $22.14

$21.91

$24.00

50 Day Range

MA: $27.04

$23.76

$30.76

2 Week Range

Now: $22.14

$21.91

$59.91

Volume

688,201 shs

Average Volume

2,045,658 shs

Market Capitalization

$2.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92